Saidal, a leading Algerian pharmaceutical company, has announced the launch of its new drug, Dapaflux, designed to manage type 2 diabetes and prevent its cardiovascular and kidney complications. This development is part of Saidal's efforts to diversify its pharmaceutical production and provide treatments with added therapeutic value. The launch was celebrated with a scientific conference in Algiers, attended by prominent figures in the healthcare sector.
The Algerian Minister of Pharmaceutical Industry, represented by his General Secretary, Abdelhakim Boualdis, praised Saidal's efforts in developing innovative drugs that meet patients' therapeutic needs. He highlighted the growing challenge of type 2 diabetes, which requires a comprehensive approach to patient care, including early detection, regular medical follow-up, and prevention of complications.
Minister Boualdis emphasized the importance of improving the quality of life for diabetes patients and reducing the burden on the healthcare system. He stressed the need for preventive measures and suitable treatments, prioritizing the pharmaceutical and economic aspects of patient care. The minister also acknowledged the pivotal role of the pharmaceutical industry in supporting prevention and treatment efforts.
Saidal's General Manager, Yunes Bouaeara, considered the launch of Dapaflux a significant milestone in the company's development, reflecting its commitment to diversifying therapeutic areas and enhancing its industrial and technological capabilities. He emphasized that this step aligns with Saidal's strategy to strengthen its position in the national market and ensure citizens' access to quality drugs at affordable prices.
A scientific conference was organized to discuss ways to improve care for type 2 diabetes patients and reduce complications. Experts highlighted the therapeutic benefits of Saidal's products, including Dapaflux, and their role in supporting medical practice and patient monitoring. The conference brought together specialists to address various medical and therapeutic aspects of the disease.
The launch of Dapaflux demonstrates Saidal's commitment to innovation and investment in research and development, enabling it to keep pace with developments in the pharmaceutical industry. This new drug is expected to contribute to the prevention of cardiovascular and kidney complications in type 2 diabetes patients, improving their quality of life and reducing healthcare costs.
The Algerian government continues to support scientific and industrial initiatives aimed at developing national production and improving patient care. The Ministry of Pharmaceutical Industry reaffirmed its commitment to accompanying Saidal and other pharmaceutical companies in their efforts to enhance the national healthcare system and promote innovation in the sector.
Key points
- Saidal launches Dapaflux, a new drug to prevent cardiovascular and kidney complications in type 2 diabetes patients.